Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Document Type
- Doctoral Thesis (2)
Language
- English (2) (remove)
Keywords
- PAF1c (2) (remove)
Institute
- Graduate School of Life Sciences (2) (remove)
The expression of the MYC proto-oncogene is elevated in a large proportion of patients with pancreatic ductal adenocarcinoma (PDAC). Previous findings in PDAC have shown that this increased MYC expression mediates immune evasion and promotes S-phase progression. How these functions are mediated and whether a downstream factor of MYC mediates these functions has remained elusive. Recent studies identifying the MYC interactome revealed a complex network of interaction partners, highlighting the need to identify the oncogenic pathway of MYC in an unbiased manner.
In this work, we have shown that MYC ensures genomic stability during S-phase and prevents transcription-replication conflicts. Depletion of MYC and inhibition of ATR kinase showed a synergistic effect to induce DNA damage. A targeted siRNA screen targeting downstream factors of MYC revealed that PAF1c is required for DNA repair and S-phase progression. Recruitment of PAF1c to RNAPII was shown to be MYC dependent. PAF1c was shown to be largely dispensable for cell proliferation and regulation of MYC target genes.
Depletion of CTR9, a subunit of PAF1c, caused strong tumor regression in a pancreatic ductal adenocarcinoma model, with long-term survival in a subset of mice. This effect was not due to induction of DNA damage, but to restoration of tumor immune surveillance.
Depletion of PAF1c resulted in the release of RNAPII with transcription elongation factors, including SPT6, from the bodies of long genes, promoting full-length transcription of short genes. This resulted in the downregulation of long DNA repair genes and the concomitant upregulation of short genes, including MHC class I genes. These data demonstrate that a balance between long and short gene transcription is essential for tumor progression and that interference with PAF1c levels shifts this balance toward a tumor-suppressive transcriptional program. It also directly links MYC-mediated S-phase progression to immune evasion. Unlike MYC, PAF1c has a stable, known folded structure; therefore, the development of a small molecule targeting PAF1c may disrupt the immune evasive function of MYC while sparing its physiological functions in cellular growth.
The oncogene MYC is deregulated and overexpressed in a high variety of human
cancers and is considered an important driver in tumorigenesis. The MYC protein
binds to virtually all active promoters of genes which are also bound by the RNA
Polymerase II (RNAPII). This results in the assumption that MYC is a transcription
factor regulating gene expression. The effects of gene expression are weak and often
differ depending on the tumor entities or MYC levels. These observations could
argue that the oncogene MYC has additional functions independent of altering gene
expression. In relation to this, the high diversity of interaction partners might be
important. One of them is the RNAPII associated Factor I complex (PAF1c).
In this study, direct interaction between PAF1c and MYC was confirmed in an
in-vitro pulldown assay. ChIP sequencing analyses revealed that knockdown of PAF1c
components resulted in reduced MYC occupancy at active promoters. Depletion
or activation as well as overexpression of MYC led to reduced or enhanced global
occupancy of PAF1c in the body of active genes, arguing that MYC and PAF1c
bind cooperatively to chromatin. Upon PAF1c knockdown cell proliferation was
reduced and additionally resulted in an attenuation of activation or repression of
MYC-regulated genes. Interestingly, knockdown of PAF1c components caused an
accumulation in S-phase of cells bearing oncogenic MYC levels. Remarkably, enhanced
DNA damage, measured by elevated gH2AX and pKAP1 protein levels, was observed
in those cells and this DNA damage occurs specifically during DNA synthesis.
Strikingly, MYC is involved in double strand break repair in a PAF1c-dependent
manner at oncogenic MYC levels.
Collectively the data show that the transfer of PAF1c from MYC onto the RNAPII
couples the transcriptional elongation with double strand break repair to maintain
the genomic integrity in MYC-driven tumor cells.